Kongsberg Beam Technology is on an important mission to develop the next generation´s radiation therapy with improved cancer treatment and less side effects for patients.
The possibilities of performing high-precision and adaptive radiotherapy have improved in recent years. Today more people are living with treated cancer but the outcome is, unfortunately that many of them suffer from severe health problems which is a result from radiation of healthy tissue.
Despite the research and development that has been done, the radiation is still sent out into a “black box”.
We are developing our MaMa-K™ software, an AI-supported software solution that can substantially enhance the performance of established treatment equipment and dose-planning systems. With MaMa-K it is possible to monitor and predict the anatomical and functional changes of a tumour and surrounding tissue, e,g. organ at risk between treatment sessions. The MaMa-K software will further allow real-time optimisation of radiation.
Chairman of the board
Aud Trondvold holds a master’s degree in engineering (electronics/radio systems) from NTNU and an EMBA from SKEMA Business School. Aud Trondvold serves as Vice President Emerging Projects at Kongsberg Maritime. Previous positions at the Kongsberg group includes Group Innovation Manager at Kongsberg Gruppen ASA, Manager PMO Kongsberg Maritime and Project Manager Kongsberg Defence& Aerospace, Space Department.. Aud Trondvold has also held board positions in Kongsberg Innovasjon and Proneo.
Trond Hellum is educated as a lawyer from University of Oslo. He has many years‘ experience from investment banking and financial advisory. Trond has been the lead manager at Bergen Bank Securities as well as the lead manager of DNB Securities’ brokerage division. Trond was one of Saga Corporate Finance’s founders and has worked with corporate finance and M&A since 1991. Trond held the position as Chairman of the Board of Kongsberg Devotek AS from 2001 until Semcon AB took over the ownership in 2015.
Christen Harr holds a master’s degree in civil engineering from NTNU. He currently operates from his own consultancy firm as a senior adviser to major industries. Recent engagements include various projects for Marine Division in Alfa Laval and Integration Manager for Integrating Frank Mohn AS into Alfa Laval. Other positions in the Alfa Laval Corporate AB includes General Manager Channel Management and General Manager Segment Comfort and Refrigeration. As CEO for Alfa Laval Nordic
Christen Harr was responsible for the Alfa Laval sales and service in the five Nordic Countries (Sweden, Finland, Denmark, Iceland and Norway) € 250 million turnover.
Thomas Andersson holds a master´s degree in chemistry and a Ph.D. in biophysics from Lund University. He currently serves as Senior Adviser at Oslo Cancer Cluster. Thomas Andersson has more than 30 years’ experience from national and international Biotech and Medtech development. Thomas Andersson´s past engagement at CEO/Board level in the Biotech/Medtech sector includes SpectraCure AB, VibroSence Dynamics AB, Cantargia and Follicum AB. Thomas Andersson has more than 10 years’ experience from commercialization of and investments in early Biotech and Medtech innovations from Karolinska Innovations AB, Karolinska Development AB and Lund University Bioscience AB.
Christian Bryn is the founding partner and CEO of Positron Capital in Oslo, a specialized, independent asset manager within Private Markets investments, and Executive Director of the Hektor / Vindeggen group of investment companies in Oslo, which focus on direct investments in private enterprises with a sustainable business model.
Christian has more than 20 years of experience from private investments, business development, strategy, and active ownership, and he was previously with PriceWaterhouseCoopers in Zurich and Clariden Bank (Credit Suisse group) in Zurich.
Chief Executive Officer
Kerstin Jakobsson holds a master’s degree in biochemistry from Lund University. She has hands-on experience from the Medtech industry in Sweden as CEO for start-up companies and a proven track record of bringing a concept from idea to clinical testing and regulatory approval. Kerstin Jakobsson has worked with business development and strategies in the life science segment and commercialized new products/services worldwide.
Kerstin Jakobsson past engagement as CEO and Board level in the Biotech/Medtech sector including eg Medicon Village Science Park, SpectraCure AB, Oncodia AB, Ortoma AB, Glycorex Transplantation AB, SmiLe incubator och STIL foundation and TEM foundation. She has also been part of the management team of Foss/Tecator AB, Perstorp Analytic AB, ReadSoft AB, HemoCue AB. She has more than 10 years’ experience from building the largest life science park and community in the Nordic countries – Medicon Village. She is and has been part of several different external advisory bords of Lund University such as LTHs business council, Crate Health, Foundation board Entrepreneurship (Sten K. Johnssons) and NanoLund. Kerstin Jakobsson is board member of the MedTech companies DiagonalBio and ProstaLund.
Per Håvard Kleven, graduated from Norges Handelshøyskole as “siviløkonom” in 1975. During most of his career he has been managing technical projects, technical departments in larger corporations and smaller technology focused companies.
In 2001 he established Kongsberg Devotek, of which he held the ownership and management responsibilities until December 2015.
Per Håvard Kleven, graduated from Norges Handelshøyskole as “siviløkonom” in 1975. During most of his career he has been managing technical projects, technical departments in larger corporations and smaller technology focused companies.
In 2001 he established Kongsberg Devotek, of which he held the ownership and management responsibilities until December 2015.
About Kongsberg Beam Technology
Kongsberg Beam Technology strives to become a premier partner for leading companies within the radiation therapy industry. Based on its AI-supported software solution, MaMa-K can substantially enhance the performance and safety of established treatment equipment and dose-planning systems. MaMa-K makes it possible to monitor and predict anatomical and functional changes of a tumour and surrounding tissue, e.g. organs at risk, between treatment sessions. The MaMa-K software will further allow real-time optimisation of delivered radiation. With these unique properties, MaMa-K has the potential to significantly improve treatment outcomes and limit severe short- and long-term side effects.